ArticleCell death & disease2019

Targeting HDAC/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer.

Yuhong Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.